Loading...
XHEL
REG1V
Market cap678mUSD
Apr 09, Last price  
22.70EUR
1D
-3.61%
1Q
-15.61%
Jan 2017
123.43%
Name

Revenio Group Oyj

Chart & Performance

D1W1MN
P/E
32.63
P/S
5.83
EPS
0.70
Div Yield, %
1.67%
Shrs. gr., 5y
0.74%
Rev. gr., 5y
15.91%
Revenues
104m
+7.17%
22,591,22318,444,36011,456,00045,146,00029,977,00029,434,00033,281,00025,382,00025,727,00016,031,00020,250,00023,434,00026,791,00030,658,00049,474,00061,067,00078,778,00096,976,00096,576,000103,500,000
Net income
19m
-3.19%
002,272,0002,665,000-815,000-507,0003,911,000-287,0004,338,000-694,0006,497,0005,584,0006,850,0008,103,0009,343,00013,362,00017,321,00021,753,00019,109,00018,500,000
CFO
24m
+120.03%
001,001,0003,279,0001,956,0001,274,0004,229,000774,0005,483,0002,763,0006,811,0006,046,0007,870,00010,416,00012,489,00015,230,00021,509,00023,241,00010,862,00023,900,000
Dividend
Apr 05, 20240.38 EUR/sh
Earnings
Apr 23, 2025

Profile

Revenio Group Oyj, a health technology company, designs, manufactures, and sells ophthalmic diagnostics and devices for the detection of glaucoma, macular degeneration, diabetic retinopathy, and cataracts in Finland, rest of Europe, and internationally. The company offers iCare IC100 and IC200 tonometers; iCare HOME, a device for self-measurement of eye pressure; imaging devices comprising iCare EIDON AF, a device with confocal retinal imaging; DRSplus, a device for detection of diabetic retinopathy; iCare MAIA, a microperimeter to measure the visual field; and iCare COMPASS, which provides fundus perimetry with true-color confocal retinal images. It also provides Oculo, an eye care software platform, which combines clinical communication, telehealth, remote patient monitoring and data analytics capabilities. Revenio Group Oyj was incorporated in 2001 and is based in Vantaa, Finland.
URL
https://www.reveniogroup.fi/
IPO date
Jan 01, 2003
Employees
217
Domiciled in
FI
Incorporated in
FI

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
103,500
7.17%
96,576
-0.41%
96,976
23.10%
Cost of revenue
30,600
43,770
41,450
Unusual Expense (Income)
NOPBT
72,900
52,806
55,526
NOPBT Margin
70.43%
54.68%
57.26%
Operating Taxes
6,100
6,274
7,303
Tax Rate
8.37%
11.88%
13.15%
NOPAT
66,800
46,532
48,223
Net income
18,500
-3.19%
19,109
-12.15%
21,753
25.59%
Dividends
(10,100)
(9,572)
(9,036)
Dividend yield
1.43%
1.32%
0.88%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
1,300
5,563
5,080
Long-term debt
4,300
16,017
16,860
Deferred revenue
Other long-term liabilities
6,900
702
739
Net debt
(15,100)
(2,298)
(10,715)
Cash flow
Cash from operating activities
23,900
10,862
23,241
CAPEX
(1,200)
(653)
(1,996)
Cash from investing activities
(8,800)
(5,975)
(2,155)
Cash from financing activities
(16,100)
(15,006)
(14,141)
FCF
75,400
35,263
44,138
Balance
Cash
20,700
21,542
32,062
Long term investments
2,336
593
Excess cash
15,525
19,049
27,806
Stockholders' equity
57,500
101,625
92,823
Invested Capital
101,875
99,462
83,116
ROIC
66.36%
50.97%
58.80%
ROCE
60.25%
43.36%
48.46%
EV
Common stock shares outstanding
26,658
26,593
26,580
Price
26.58
-2.21%
27.18
-29.59%
38.60
-30.51%
Market cap
708,578
-1.97%
722,792
-29.55%
1,026,002
-30.45%
EV
693,478
720,494
1,015,287
EBITDA
78,100
56,750
58,960
EV/EBITDA
8.88
12.70
17.22
Interest
763
263
Interest/NOPBT
1.44%
0.47%